Cogent Biosciences recently released its 10-Q report. Cogent is a clinical-stage biotechnology company focused on precision therapies for genetically defined diseases. Its lead program is bezuclastinib, a selective KIT inhibitor being developed for systemic mastocytosis and gastrointestinal stromal tumors, and it also has early-stage programs targeting FGFR2, mutant ErbB2, PI3Kα, KRAS, and JAK2.
In Item 2, Management’s Discussion and Analysis, Cogent said it has not generated revenue from product sales and continues to operate at a loss. Net loss widened to $97.4 million for the three months ended March 31, 2026, from $72.0 million a year earlier, and the accumulated deficit reached $1.286 billion at quarter-end. The company said it expects expenses and capital needs to rise as it pursues regulatory approvals, builds commercial infrastructure, expands manufacturing and supply chain capacity, and advances its clinical pipeline.
Bezuclastinib remained the centerpiece of the filing. Cogent said the drug is designed to inhibit KIT D816V and other KIT exon 17 mutations, which are tied to systemic mastocytosis and advanced GIST. The company reported positive top-line results in 2025 from registrational trials in NonAdvSM, AdvSM, and GIST, and said it believes the drug could support a global annual market opportunity of more than $4 billion in GIST in combination with sunitinib, about $3.5 billion in NonAdvSM, and about $500 million in AdvSM.
Cogent said it submitted its first NDA for bezuclastinib in NonAdvSM in December 2025, with FDA acceptance in March 2026 and a PDUFA date of December 30, 2026. It expects to submit an NDA for AdvSM in the first half of 2026. For GIST, the company said the FDA accepted the NDA under the Real-Time Oncology Review program in January 2026, and the filing was submitted in March 2026; the agency also granted Breakthrough Therapy Designation in January 2026.
The company also disclosed milestone payments tied to its Plexxikon license for bezuclastinib. A $5.0 million regulatory milestone became payable in the fourth quarter of 2025 and was paid in the first quarter of 2026, and Cogent said another $15.0 million could become payable over the next 12 months if additional regulatory milestones are reached. Cogent said worldwide rights to bezuclastinib are exclusively licensed from Plexxikon.
On the pipeline beyond bezuclastinib, Cogent said it initiated a Phase 1 dose-escalation study for CGT4255, its mutant ErbB2 program, in the fourth quarter of 2025, and started a Phase 1 dose-escalation study for CGT6297, its PI3Kα inhibitor, in the first quarter of 2026. It also said IND-enabling work for CGT6297 was completed and the IND was submitted in the fourth quarter of 2025. As a result of these announcements, the company's shares have moved -1.66% on the market, and are now trading at a price of $36.12. If you want to know more, read the company's complete 10-Q report here.
